Back

CHA2DS2-VASc versus R2CHADS2 at predicting thromboembolic event in a cohort of non-anticoagulated patients with non-valvular atrial fibrillation

28 August 2016 (14:00 - 18:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Anticoagulation in atrial fibrillation Atrial fibrillation (AF) ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Francisco Javier Garcia Seara

University Hospital of Santiago de Compostela, Santiago de Compostela (Spain)

20 More presentations in this session

Presentation thumbnail
Doctor E. Ueno (Kahoku, JP)
Abstract
Presentation thumbnail
Ms G. Stynes (Uxbridge, GB)
Abstract Slides
Presentation thumbnail
Professor G. Lip (Liverpool, GB)
Abstract Slides
Presentation thumbnail
Ms G. Stynes (Uxbridge, GB)
Abstract Slides
Presentation thumbnail
Doctor M. Rohla (Bern, CH)
Abstract

Access the full session

Session thumbnail
Poster session 3 - Anticoagulation in atrial fibrillation

The Event

Event poster

ESC Congress 2016

28 August 2016 14:00 CET
You may be interested in
thumbnail
Congress Presentation
Predictors of stroke or systemic embolism in patients with non-valvular atrial fibrillation with CHA2DS2-VASc score of 0
16 April 2023
thumbnail
Webinar
Anticoagulation challenges in older subjects with multimorbidity
25 July 2023
thumbnail
Congress Presentation
Head-to-head comparison of CHADS₂, CHA₂DS₂-VASc, CHA₂DS₂-VA, HAS-BLED, and HELT-E₂S₂ scores in edoxaban treated atrial fibrillation patients: a 2-year analysis from the ETNA-AF Global program
28 August 2026
thumbnail
Congress Presentation
Clinical and prognosis assessment of Atrial Fibrillation patients with significant valvular disease. Validation of the EHRA valve classification (Evaluated Heartvalves. Rheumatic or Artificial)
29 August 2022

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources